Telithromycin. Fresh from the Pipeline

Aarti Raja; J. Lebbos; P. Kirtpatrick

Telithromycin. Fresh from the Pipeline

Aarti Raja
, J. Lebbos
, P. Kirtpatrick

Department of Biological Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

In April 2004, telithromycin (Ketek; Aventis), the first of a new class of antibacterial drugs derived from macrolides, was approved by the US FDA for the treatment of several respiratory-tract infections. After a delay in its approval owing to a need to address potential safety issues, is it likely to now attain the blockbuster status that had originally been widely predicted?

Original language	American English
Journal	Nature Reviews Drug Discovery
State	Published - Sep 1 2004

Disciplines

Biology

Access to Document

https://www.nature.com/articles/nrd1502

Cite this

@article{bacecfce19b04483951fc8b7e066775d,

title = "Telithromycin. Fresh from the Pipeline",

abstract = " In April 2004, telithromycin (Ketek; Aventis), the first of a new class of antibacterial drugs derived from macrolides, was approved by the US FDA for the treatment of several respiratory-tract infections. After a delay in its approval owing to a need to address potential safety issues, is it likely to now attain the blockbuster status that had originally been widely predicted?",

author = "Aarti Raja and J. Lebbos and P. Kirtpatrick",

year = "2004",

month = sep,

day = "1",

language = "American English",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Research",

}

TY - JOUR

T1 - Telithromycin. Fresh from the Pipeline

AU - Raja, Aarti

AU - Lebbos, J.

AU - Kirtpatrick, P.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - In April 2004, telithromycin (Ketek; Aventis), the first of a new class of antibacterial drugs derived from macrolides, was approved by the US FDA for the treatment of several respiratory-tract infections. After a delay in its approval owing to a need to address potential safety issues, is it likely to now attain the blockbuster status that had originally been widely predicted?

AB - In April 2004, telithromycin (Ketek; Aventis), the first of a new class of antibacterial drugs derived from macrolides, was approved by the US FDA for the treatment of several respiratory-tract infections. After a delay in its approval owing to a need to address potential safety issues, is it likely to now attain the blockbuster status that had originally been widely predicted?

UR - https://nsuworks.nova.edu/cnso_bio_facarticles/71

M3 - Article

SN - 1474-1776

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

ER -

Telithromycin. Fresh from the Pipeline

Abstract

Disciplines

Access to Document

Other files and links

Fingerprint

Cite this